Addex Therapeutics Ltd (ADXN)
8.79
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
8.78
-0.01
(-0.11%)
After-Hours: 20:00
Addex Therapeutics Research and Development Expense (Quarterly): 0.5126M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.5126M |
| September 30, 2023 | 0.9438M |
| June 30, 2023 | 0.8365M |
| March 31, 2023 | 0.7653M |
| December 31, 2022 | 1.151M |
| September 30, 2022 | 1.799M |
| June 30, 2022 | 4.847M |
| March 31, 2022 | 2.714M |
| December 31, 2021 | 2.677M |
| September 30, 2021 | 1.967M |
| Date | Value |
|---|---|
| June 30, 2021 | 4.098M |
| March 31, 2021 | 3.038M |
| December 31, 2020 | 2.791M |
| September 30, 2020 | 2.152M |
| June 30, 2020 | 2.406M |
| March 31, 2020 | 3.672M |
| December 31, 2019 | 5.925M |
| September 30, 2019 | 2.201M |
| June 30, 2019 | 3.402M |
| March 31, 2019 | 1.807M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.5126M
Minimum
Dec 2023
5.925M
Maximum
Dec 2019
2.521M
Average
2.406M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| AC Immune SA | 17.35M |
| CRISPR Therapeutics AG | 76.17M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 14.50M |
| MoonLake Immunotherapeutics | 13.01M |